241 related articles for article (PubMed ID: 29037480)
1. Linking energy sensing to suppression of JAK-STAT signalling: A potential route for repurposing AMPK activators?
Speirs C; Williams JJL; Riches K; Salt IP; Palmer TM
Pharmacol Res; 2018 Feb; 128():88-100. PubMed ID: 29037480
[TBL] [Abstract][Full Text] [Related]
2. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
Roskoski R
Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738
[TBL] [Abstract][Full Text] [Related]
3. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
Roskoski R
Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
[TBL] [Abstract][Full Text] [Related]
4. AICAR, an AMPK activator, protects against cisplatin-induced acute kidney injury through the JAK/STAT/SOCS pathway.
Tsogbadrakh B; Ryu H; Ju KD; Lee J; Yun S; Yu KS; Kim HJ; Ahn C; Oh KH
Biochem Biophys Res Commun; 2019 Feb; 509(3):680-686. PubMed ID: 30616891
[TBL] [Abstract][Full Text] [Related]
5. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
6. Role of JAK-STAT pathway in reducing cardiomyocytes hypoxia/reoxygenation injury induced by S1P postconditioning.
Wang Y; Wang D; Zhang L; Ye F; Li M; Wen K
Eur J Pharmacol; 2016 Aug; 784():129-36. PubMed ID: 27215146
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation of Janus kinase 1 (JAK1) by AMP-activated protein kinase (AMPK) links energy sensing to anti-inflammatory signaling.
Rutherford C; Speirs C; Williams JJ; Ewart MA; Mancini SJ; Hawley SA; Delles C; Viollet B; Costa-Pereira AP; Baillie GS; Salt IP; Palmer TM
Sci Signal; 2016 Nov; 9(453):ra109. PubMed ID: 27919027
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds.
Migita K; Izumi Y; Torigoshi T; Satomura K; Izumi M; Nishino Y; Jiuchi Y; Nakamura M; Kozuru H; Nonaka F; Eguchi K; Kawakami A; Motokawa S
Clin Exp Immunol; 2013 Dec; 174(3):356-63. PubMed ID: 23968543
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological activation of AMPK ameliorates perivascular adipose/endothelial dysfunction in a manner interdependent on AMPK and SIRT1.
Sun Y; Li J; Xiao N; Wang M; Kou J; Qi L; Huang F; Liu B; Liu K
Pharmacol Res; 2014 Nov; 89():19-28. PubMed ID: 25108154
[TBL] [Abstract][Full Text] [Related]
10. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Lai SY; Johnson FM
Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
[TBL] [Abstract][Full Text] [Related]
11. Sitagliptin and tofacitinib ameliorate adjuvant induced arthritis via modulating the cross talk between JAK/STAT and TLR-4/NF-κB signaling pathways.
Ibrahim SSA; Salama MA; Selima E; Shehata RR
Life Sci; 2020 Nov; 260():118261. PubMed ID: 32795539
[TBL] [Abstract][Full Text] [Related]
12. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.
Coskun M; Salem M; Pedersen J; Nielsen OH
Pharmacol Res; 2013 Oct; 76():1-8. PubMed ID: 23827161
[TBL] [Abstract][Full Text] [Related]
13. Dynamics and non-canonical aspects of JAK/STAT signalling.
Mohr A; Chatain N; Domoszlai T; Rinis N; Sommerauer M; Vogt M; Müller-Newen G
Eur J Cell Biol; 2012; 91(6-7):524-32. PubMed ID: 22018664
[TBL] [Abstract][Full Text] [Related]
14. An insight into JAK-STAT signalling in dermatology.
Palanivel JA; Macbeth AE; Chetty NC; Levell NJ
Clin Exp Dermatol; 2014 Jun; 39(4):513-8. PubMed ID: 24825142
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic targeting of the Jak/STAT pathway.
Aittomäki S; Pesu M
Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):18-23. PubMed ID: 24164900
[TBL] [Abstract][Full Text] [Related]
16. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours.
Thomas SJ; Snowden JA; Zeidler MP; Danson SJ
Br J Cancer; 2015 Jul; 113(3):365-71. PubMed ID: 26151455
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of JAK/STAT pathway modulation in mood disorders.
Shariq AS; Brietzke E; Rosenblat JD; Pan Z; Rong C; Ragguett RM; Park C; McIntyre RS
Rev Neurosci; 2018 Dec; 30(1):1-7. PubMed ID: 29902157
[TBL] [Abstract][Full Text] [Related]
18. Targeting SOCS Proteins to Control JAK-STAT Signalling in Disease.
Durham GA; Williams JJL; Nasim MT; Palmer TM
Trends Pharmacol Sci; 2019 May; 40(5):298-308. PubMed ID: 30948191
[TBL] [Abstract][Full Text] [Related]
19. JAK/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance.
Sabaawy HE; Ryan BM; Khiabanian H; Pine SR
Carcinogenesis; 2021 Dec; 42(12):1411-1419. PubMed ID: 34415330
[TBL] [Abstract][Full Text] [Related]
20. Therapeutics targeting innate immune/inflammatory responses through the interleukin-6/JAK/STAT signal transduction pathway in patients with cancer.
Roxburgh CS; McMillan DC
Transl Res; 2016 Jan; 167(1):61-6. PubMed ID: 26432924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]